MARKET

YARW

YARW

YARROW BIOSCIENCE, INC.
NASDAQ
27.01
-1.43
-5.03%
After Hours: 27.01 0 0.00% 19:30 09/11 EDT
OPEN
26.60
PREV CLOSE
28.44
HIGH
27.49
LOW
26.00
VOLUME
1.36M
TURNOVER
--
52 WEEK HIGH
46.95
52 WEEK LOW
14.02
MARKET CAP
72.11M
P/E (TTM)
-1.2364
1D
5D
1M
3M
1Y
5Y
1D
Yarrow Bioscience prices $150M public offering of common stock at $26 per share
Seeking Alpha · 1d ago
*Jefferies, TD Cowen, Guggenheim Securities Among Mangers for Offering >YARW
Dow Jones · 1d ago
*Yarrow Bioscience Offering Is Expected to Close on September 14 >YARW
Dow Jones · 1d ago
*Yarrow Bioscience Intends to Use Proceeds to Fund R&D Expenses for Pipeline >YARW
Dow Jones · 1d ago
*Yarrow Bioscience Has Granted Underwriters Option for Additional 865,384 Shares >YARW
Dow Jones · 1d ago
*Yarrow Bioscience Offering of 5,769,231 Shares Priced at $26.00 Each >YARW
Dow Jones · 1d ago
Yarrow Bioscience 5.77M share Spot Secondary priced at $26.00
TipRanks · 1d ago
Yarrow Bioscience Updates Strategy for Thyroid Autoimmune Pipeline
TipRanks · 1d ago
More
About YARW
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, an anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' Disease (GD) and Thyroid Eye Disease (TED), offering a single targeted treatment to address both diseases. By blocking TSHR, the common target of autoantibodies in both the thyroid and the eye, YB-101 has the potential to rapidly arrest the disease process and provide improved efficacy and safety versus the standard of care and other mechanisms in development. YB-101 is designed for convenient subcutaneous administration, with the potential for infrequent dosing and future autoinjector presentations. The Company has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED.

Webull offers Yarrow Bioscience Inc stock information, including NASDAQ: YARW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YARW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading YARW stock methods without spending real money on the virtual paper trading platform.